Pain Medicine, Interventional Pain Medicine · Hoover, AL
NPI
1013068881
Since 2007
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4515 Southlake Pkwy Ste 200
Hoover, AL, 35244
Phone (205) 313-7246
Groups this clinician bills Medicare through
Medicare paid, 2024
$309K
7,036 services
Medicare patients, 2024
290
Average age 68
Drug cost, 2024
$1.3M
17,717 prescriptions
Company payments, 2025
$1,289
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael G Gibson was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 2,559 times for 99 patients. In total Michael G Gibson billed 7,036 services in 48 codes, and Medicare paid $309K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-10-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,559 | 99 | $0.09 | $225 |
| 99213 Office E&M - Established | Office | 806 | 243 | $53.58 | $43K |
| 80307 Drug Tests | Office | 712 | 228 | $59.50 | $42K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 614 | 216 | $12.32 | $7,566 |
| 99214 Office E&M - Established | Office | 574 | 198 | $78.09 | $45K |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 537 | 181 | $148.06 | $80K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 131 | 46 | $194.77 | $26K |
| 64483 Nerve Block Injection - Back | Office | 66 | 47 | $227.86 | $15K |
| 64484 Nerve Block Injection - Back | Office | 56 | 32 | $109.50 | $6,132 |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 47 | 33 | $112.14 | $5,271 |
| 82947 Clinical Chemistry | Office | 34 | 20 | $3.06 | $104 |
| 20610 Joint Injection | Office | 33 | 24 | $51.62 | $1,704 |
| 62321 Nerve Block Injection - Back | Office | 32 | 26 | $162.23 | $5,191 |
| 80053 Clinical Chemistry | Office | 28 | 28 | $9.95 | $279 |
| 77002 Imaging - Miscellaneous | Office | 26 | 20 | $79.32 | $2,062 |
By year: 2022 $454K for 14,943 services; 2023 $392K for 12,459 services; 2024 $309K for 7,036 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80307 Drug Tests | 712 | 228 | $59.50 | $42K |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 537 | 181 | $148.06 | $80K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 131 | 46 | $194.77 | $26K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 47 | 33 | $112.14 | $5,271 |
| 82947 Clinical Chemistry | 34 | 20 | $3.06 | $104 |
| 80053 Clinical Chemistry | 28 | 28 | $9.95 | $279 |
| 85025 Blood Count | 21 | 21 | $7.60 | $160 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael G Gibson prescribed most often to Medicare patients was Oxycodone-Acetaminophen (Oxycodone Hcl/Acetaminophen), with 2,481 prescriptions and refills. In total Michael G Gibson wrote 17,717 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 2,481 | 2,488 | 327 | $89K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 2,288 | 2,300 | 283 | $73K |
| Gabapentin Generic | 1,669 | 1,930 | 269 | $22K |
| Tizanidine Hcl Generic | 1,147 | 1,369 | 191 | $13K |
| Oxycodone Hcl Generic | 1,136 | 1,136 | 148 | $33K |
| Morphine Sulfate Er Morphine Sulfate | 688 | 688 | 81 | $36K |
| Methocarbamol Generic | 559 | 602 | 107 | $10K |
| Fentanyl Generic | 510 | 510 | 65 | $63K |
| Methadone Hcl Generic | 500 | 504 | 54 | $17K |
| Pregabalin Generic | 418 | 450 | 70 | $7,766 |
| Duloxetine Hcl Generic | 417 | 456 | 67 | $5,989 |
| Trazodone Hcl Generic | 415 | 488 | 71 | $2,348 |
| Cyclobenzaprine Hcl Generic | 322 | 346 | 55 | $4,492 |
| Meloxicam Generic | 322 | 390 | 55 | $1,572 |
| Celecoxib Generic | 275 | 339 | 61 | $8,751 |
Brand drugs: 1,042 claims; generic drugs: 16,675 claims; opioid claims: 8,601.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael G Gibson $1,289 ($1,289 in general payments such as food, travel and fees) from 16 companies. The largest payer was BIOTRONIK NRO, Inc. with $204.
| Company | Payments | Amount |
|---|---|---|
| BIOTRONIK NRO, Inc. | 3 | $204 |
| Abbott Laboratories ABT | 10 | $185 |
| SPR Therapeutics, Inc | 8 | $152 |
| Pfizer Inc. PFE | 5 | $120 |
| Boston Scientific Corporation BSX | 4 | $112 |
| Forte Bio-Pharma LLC | 4 | $83.69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 4 | $79.49 |
| Saluda Medical Americas, Inc. | 3 | $66.44 |
| Collegium Pharmaceutical, Inc. COLL | 3 | $65.68 |
| Protega Pharmaceutials Inc | 3 | $55.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.